No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
002581 Shandong Sinobioway Biomedicine
- 10.58
- +0.02+0.19%
Market Closed Jun 7 15:00 CST
6.98BMarket Cap-20623P/E (TTM)
10.75High10.40Low29.00KlotVolume10.53Open10.56Pre Close30.68MTurnover0.72%Turnover RatioLossP/E (Static)659.74MShares20.2852wk High3.41P/B4.24BFloat Cap8.5452wk Low11.62Limit Up400.79MShs Float71.85Historical High9.50Limit Down3.31%Amplitude4.39Historical Low--Dividend TTM10.58Avg Price15.65KlotAsk--Div YieldTTM100Lot Size13.42KlotBid
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Unnamed Pharmaceutical (002581.SZ) withdraws from Qianhai Weiming M&A Fund
Unnamed Pharmaceutical (002581.SZ) issued an announcement, and the company held the 5th term of directors on May 30, 2024...
Unnamed Pharmaceutical (002581.SZ) received a dividend of 215 million yuan from the participating company Beijing Kexing
Unnamed Pharmaceutical (002581.SZ) announced that the company received a shareholding company, Beijing Kexing Biological Products Co., Ltd. (abbreviation...
Shareholders Have Faith in Loss-making Shandong Sinobioway Biomedicine (SZSE:002581) as Stock Climbs 10% in Past Week, Taking Five-year Gain to 83%
Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying the right stocks can give your wealth a significant boost. For example, long ter
Unnamed Pharmaceutical (002581.SZ): Net loss of 27.704 million yuan in the first quarter
On April 30, Ge Longhui Pharmaceutical (002581.SZ) released its report for the first quarter of 2024, achieving operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net profit attributable to shareholders of listed companies - 27.704 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 28.33 million yuan, and basic earnings per share - 0.042 yuan.
Unnamed Pharmaceutical (002581.SZ) reported first-quarter results with a net loss of 27.7041 million yuan
According to Zhitong Finance App, Unnamed Pharmaceutical (002581.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net loss attributable to shareholders of listed companies was 27.7041 million yuan; net loss attributable to shareholders of listed companies deducted 28.33 million yuan for non-recurring profit and loss; basic loss per share was 0.0420 yuan/share.
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up rece
Comments
Shandong Sinobioway Biomedicine's high P/S ratio and slower growth rate may pose a risk to its share price. Overvaluation and continuation of recent revenue trends could negatively impact the share price.
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected 1
Despite the recent sell-off, long-term investors may see this as an opportunity given the company's 13% annual return over five years. It's suggested to check the fundamental data for signs of a long term growth trend.
Shandong Sinobioway Biomedicine's high P/S ratio indicates a potential risk of share price decrease. Investors might pay excessive premium if recent medium-term revenue trends persist. The expected business turnaround could lead to disappointment if the P/S ratio aligns more with recent growth rates.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg